Medtronic earns expanded FDA nod for deep brain stim
December 5, 2025
Medtronic (NYSE: MDT)+
announced that the FDA approved expanded labeling for its deep brain stimulation (DBS) offering.
Medtronic (NYSE: MDT)+
announced that the FDA approved expanded labeling for its deep brain stimulation (DBS) offering.
Cardiawave announced that it received CE mark approval for Valvosoft, its non-invasive therapeutic alternative for treating aortic stenosis (AS).
CAESAREA, Israel, Dec. 5, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled “Cryogen Flow Control” which relates to its next-generation XSense™ cryoablation system and probes.
Insulet (Nasdaq: PODD)+
announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system.
Atraverse Medical announced today that it received FDA clearance for its fully integrated Hotwire transseptal access system.
Boston Scientific (NYSE: BSX)+
announced recently that it received CE mark for its Farapoint pulsed field ablation (PFA) catheter.
The trial will enroll patients who are undergoing nerve management procedures for severe neuropathic pain.
MED-EL’s cochlear implants are now FDA-approved in children seven months and older with bilateral sensorineural hearing loss (SNHL).
The approval is a major endorsement of Biomoneta’s scientific breakthrough and an important inflection point for Beyond Next Ventures India (BNV India)
Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities